$117.75-1.50 (-1.25%)
agilon health, inc.
agilon health, inc. in the Healthcare sector is trading at $117.75 with a market capitalization of $1.8B. Wall Street consensus targets $60.36 (14 analysts), implying a -48.7% move over the next 12 months. The stock is currently near its 52-week high of $125.71, remaining 258.4% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.42B↓ | $1.57B↑ | $1.44B↑ | $1.39B↓ | $1.53B |
| Gross Profit | $65.02M↑ | -$90.67M↓ | -$67.65M↓ | -$52.43M↓ | $50.72M |
| Operating Income | $4.00M↑ | -$157.74M↓ | -$131.27M↓ | -$116.03M↓ | -$22.11M |
| Net Income | $48.92M↑ | -$188.88M↓ | -$110.21M↓ | -$104.37M↓ | $12.11M |
agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-mon...
What a time it’s been for agilon health. In the past six months alone, the company’s stock price has increased by a massive 538%, setting a new 52-week high of $117.62 per share. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
Does Agilon Health (AGL) have what it takes to be a top stock pick for momentum investors? Let's find out.
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Agilon (AGL) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have realized strong financial performance, and over the past six months, the industry’s 7.6% return has closely followed the S&P 500.